Management of Chronic Kidney Disease Stage 3
For a patient with CKD stage 3, initiate an SGLT2 inhibitor if eGFR ≥20 ml/min/1.73 m² with albuminuria ≥200 mg/g or heart failure, start a RAS inhibitor (ACEi or ARB) if albuminuria is present, target systolic blood pressure <120 mmHg when tolerated, prescribe a statin for cardiovascular protection, and restrict sodium intake to <2 g/day. 1, 2
Core Pharmacologic Interventions
SGLT2 Inhibitors - First-Line Therapy
SGLT2 inhibitors are now recommended for most CKD patients regardless of diabetes status 1:
Strong indication (1A): Start if eGFR ≥20 ml/min/1.73 m² AND either:
- Urine albumin-to-creatinine ratio (ACR) ≥200 mg/g, OR
- Heart failure (any albuminuria level)
Moderate indication (2B): Consider if eGFR 20-45 ml/min/1.73 m² with ACR <200 mg/g
Key implementation points 1:
- Continue even if eGFR drops below 20 ml/min/1.73 m² once started (unless intolerant or on dialysis)
- Withhold during prolonged fasting, surgery, or critical illness (ketosis risk)
- Initial eGFR decline is expected and not a reason to stop
RAS Inhibitors (ACEi or ARB)
Prescribe based on albuminuria status 2:
- With diabetes: Start if ACR ≥30 mg/g (moderately-to-severely increased albuminuria) - 1B recommendation
- Without diabetes:
- Start if ACR ≥300 mg/g (severely increased) - 1B recommendation
- Consider if ACR 30-300 mg/g (moderately increased) - 2C recommendation
Critical monitoring protocol 1:
- Check BP, creatinine, and potassium within 2-4 weeks of initiation or dose increase
- Use maximum tolerated dose (benefits proven at these doses in trials)
- Continue therapy unless creatinine rises >30% within 4 weeks
- Continue even when eGFR falls below 30 ml/min/1.73 m² - do not stop based on eGFR alone
- Manage hyperkalemia with potassium-lowering measures rather than stopping the drug
Never combine ACEi + ARB + direct renin inhibitor - this is contraindicated (1B) 2
Nonsteroidal MRA (Finerenone)
Add for high-risk patients with type 2 diabetes 1, 2:
- Indication: eGFR >25 ml/min/1.73 m², normal potassium, ACR >30 mg/g despite maximum tolerated RAS inhibitor (2A recommendation)
- Can be combined with RASi + SGLT2i for triple therapy
- Select patients with consistently normal potassium to minimize hyperkalemia risk
Blood Pressure Management
Target systolic BP <120 mmHg using standardized office measurement (2B recommendation) 2
Exceptions - use less intensive targets for:
- Frailty
- High fall/fracture risk
- Very limited life expectancy
- Symptomatic postural hypotension
Cardiovascular Protection
- Statins: Prescribe to reduce atherosclerotic cardiovascular disease risk 3
- Cardiovascular disease is a major cause of mortality in CKD, making this essential
Dietary Management
Sodium restriction to <2 g/day (<90 mmol/day or <5 g sodium chloride/day) - 2C recommendation 2
Exception: Do not restrict sodium in patients with sodium-wasting nephropathy
Monitoring Requirements
Essential laboratory monitoring:
- eGFR and creatinine regularly
- Urinary albumin-to-creatinine ratio (ACR) - critical for treatment decisions
- Potassium (especially with RASi/MRA)
- Hemoglobin (anemia screening)
- Phosphate, calcium, PTH (mineral bone disease)
- Lipid panel
Common pitfall: Real-world data shows suboptimal monitoring even in diagnosed CKD patients, with albuminuria testing particularly neglected 4. Don't fall into this trap - ACR testing directly determines medication choices.
Nephrotoxin Avoidance
- Avoid NSAIDs 5
- Adjust drug dosing for renal function (many antibiotics, oral hypoglycemics)
- Educate patients on "sick day" medication management 3
Referral to Nephrology
Refer promptly if 5:
- eGFR <30 ml/min/1.73 m² (approaching stage 4)
- ACR ≥300 mg/g
- Rapid eGFR decline
- Uncontrolled hypertension despite multiple agents
- Persistent hyperkalemia or other complications
Evidence Strength
The 2024 KDIGO guidelines 1, 2 represent the highest quality, most recent evidence. The shift toward SGLT2 inhibitors for non-diabetic CKD and the emphasis on continuing RASi even at lower eGFR levels reflect major advances. Research confirms that recorded CKD diagnosis and guideline-adherent management significantly reduce eGFR decline (from 3.20 to 0.74 ml/min/1.73 m²/year) and lower progression risk 6.
Critical implementation gap: Despite clear guidelines, real-world adherence remains poor, with many patients not receiving recommended monitoring or medications 4, 7. Systematic implementation of these evidence-based interventions is essential to reduce CKD progression and improve mortality outcomes.